Shortened derivatives from native antimicrobial peptide LyeTx I : In vitro and in vivo biological activity assessment

dc.contributor.authorFuscaldi, Leonardo Lima
dc.contributor.authorTeixeira de Avelar Júnior, Joaquim
dc.contributor.authorMoreira Dos Santos, Daniel
dc.contributor.authorBoff, Daiane
dc.contributor.authorSoares de Oliveira, Vívian Louise
dc.contributor.authorGuimarães Gusmão Gomes, Karla Aparecida
dc.contributor.authorde Carvalho Cruz, Rosana
dc.contributor.authorde Oliveira, Patrícia Luciana
dc.contributor.authorDelp, Johannes
dc.contributor.authorLeist, Marcel
dc.date.accessioned2020-11-17T10:58:19Z
dc.date.available2020-11-17T10:58:19Z
dc.date.issued2021eng
dc.description.abstractIn the continuing search for novel antibiotics, antimicrobial peptides are promising molecules, due to different mechanisms of action compared to classic antibiotics and to their selectivity for interaction with microorganism cells rather than with mammalian cells. Previously, our research group has isolated the antimicrobial peptide LyeTx I from the venom of the spider Lycosa erythrognatha. Here, we proposed to synthesize three novel shortened derivatives from LyeTx I (LyeTx I mn; LyeTx I mnΔK; LyeTx I mnΔKAc) and to evaluate their toxicity and biological activity as potential antimicrobial agents. Peptides were synthetized by Fmoc strategy and circular dichroism analysis was performed, showing that the three novel shortened derivatives may present membranolytic activity, like the original LyeTx I, once they folded as an alpha helix in 2.2.2-trifluorethanol and sodium dodecyl sulfate. In vitro assays revealed that the shortened derivative LyeTx I mnΔK presents the best score between antimicrobial (↓ MIC) and hemolytic (↑ EC50) activities among the synthetized shortened derivatives, and LUHMES cell-based NeuriTox test showed that it is less neurotoxic than the original LyeTx I (EC50 [LyeTx I mnΔK] ⋙ EC50 [LyeTx I]). In vivo data, obtained in a mouse model of septic arthritis induced by Staphylococcus aureus, showed that LyeTx I mnΔK is able to reduce infection, as demonstrated by bacterial recovery assay (∼10-fold reduction) and scintigraphic imaging (less technetium-99m labeled-Ceftizoxime uptake by infectious site). Infection reduction led to inflammatory process and pain decreases, as shown by immune cells recruitment reduction and threshold nociception increment, when compared to positive control group. Therefore, among the three shortened peptide derivatives, LyeTx I mnΔK is the best candidate as antimicrobial agent, due to its smaller amino acid sequence and toxicity, and its greater biological activity.eng
dc.description.versionpublishedeng
dc.identifier.doi10.1177/1535370220966963eng
dc.identifier.pmid33175610eng
dc.identifier.ppn1805522566
dc.identifier.urihttps://kops.uni-konstanz.de/handle/123456789/51821
dc.language.isoengeng
dc.rightsterms-of-use
dc.rights.urihttps://rightsstatements.org/page/InC/1.0/
dc.subjectAntimicrobial peptide, shortened derivatives from LyeTx I, LyeTx I mnΔK, septic arthritis, infection, inflammation processeng
dc.subject.ddc570eng
dc.titleShortened derivatives from native antimicrobial peptide LyeTx I : In vitro and in vivo biological activity assessmenteng
dc.typeJOURNAL_ARTICLEeng
dspace.entity.typePublication
kops.citation.bibtex
@article{Fuscaldi2021Short-51821,
  year={2021},
  doi={10.1177/1535370220966963},
  title={Shortened derivatives from native antimicrobial peptide LyeTx I : In vitro and in vivo biological activity assessment},
  number={4},
  volume={246},
  issn={1535-3702},
  journal={Experimental Biology and Medicine},
  pages={414--425},
  author={Fuscaldi, Leonardo Lima and Teixeira de Avelar Júnior, Joaquim and Moreira Dos Santos, Daniel and Boff, Daiane and Soares de Oliveira, Vívian Louise and Guimarães Gusmão Gomes, Karla Aparecida and de Carvalho Cruz, Rosana and de Oliveira, Patrícia Luciana and Delp, Johannes and Leist, Marcel}
}
kops.citation.iso690FUSCALDI, Leonardo Lima, Joaquim TEIXEIRA DE AVELAR JÚNIOR, Daniel MOREIRA DOS SANTOS, Daiane BOFF, Vívian Louise SOARES DE OLIVEIRA, Karla Aparecida GUIMARÃES GUSMÃO GOMES, Rosana DE CARVALHO CRUZ, Patrícia Luciana DE OLIVEIRA, Johannes DELP, Marcel LEIST, 2021. Shortened derivatives from native antimicrobial peptide LyeTx I : In vitro and in vivo biological activity assessment. In: Experimental Biology and Medicine. Sage Publications. 2021, 246(4), pp. 414-425. ISSN 1535-3702. eISSN 1535-3699. Available under: doi: 10.1177/1535370220966963deu
kops.citation.iso690FUSCALDI, Leonardo Lima, Joaquim TEIXEIRA DE AVELAR JÚNIOR, Daniel MOREIRA DOS SANTOS, Daiane BOFF, Vívian Louise SOARES DE OLIVEIRA, Karla Aparecida GUIMARÃES GUSMÃO GOMES, Rosana DE CARVALHO CRUZ, Patrícia Luciana DE OLIVEIRA, Johannes DELP, Marcel LEIST, 2021. Shortened derivatives from native antimicrobial peptide LyeTx I : In vitro and in vivo biological activity assessment. In: Experimental Biology and Medicine. Sage Publications. 2021, 246(4), pp. 414-425. ISSN 1535-3702. eISSN 1535-3699. Available under: doi: 10.1177/1535370220966963eng
kops.citation.rdf
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/51821">
    <dc:contributor>de Carvalho Cruz, Rosana</dc:contributor>
    <dcterms:title>Shortened derivatives from native antimicrobial peptide LyeTx I : In vitro and in vivo biological activity assessment</dcterms:title>
    <dc:language>eng</dc:language>
    <dc:contributor>Moreira Dos Santos, Daniel</dc:contributor>
    <dc:creator>Teixeira de Avelar Júnior, Joaquim</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-11-17T10:58:19Z</dc:date>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/51821/1/Fuscaldi_2-1me5tj5d3hi0l9.pdf"/>
    <dc:contributor>Delp, Johannes</dc:contributor>
    <dcterms:issued>2021</dcterms:issued>
    <dcterms:abstract xml:lang="eng">In the continuing search for novel antibiotics, antimicrobial peptides are promising molecules, due to different mechanisms of action compared to classic antibiotics and to their selectivity for interaction with microorganism cells rather than with mammalian cells. Previously, our research group has isolated the antimicrobial peptide LyeTx I from the venom of the spider Lycosa erythrognatha. Here, we proposed to synthesize three novel shortened derivatives from LyeTx I (LyeTx I mn; LyeTx I mnΔK; LyeTx I mnΔKAc) and to evaluate their toxicity and biological activity as potential antimicrobial agents. Peptides were synthetized by Fmoc strategy and circular dichroism analysis was performed, showing that the three novel shortened derivatives may present membranolytic activity, like the original LyeTx I, once they folded as an alpha helix in 2.2.2-trifluorethanol and sodium dodecyl sulfate. In vitro assays revealed that the shortened derivative LyeTx I mnΔK presents the best score between antimicrobial (↓ MIC) and hemolytic (↑ EC&lt;sub&gt;50&lt;/sub&gt;) activities among the synthetized shortened derivatives, and LUHMES cell-based NeuriTox test showed that it is less neurotoxic than the original LyeTx I (EC&lt;sub&gt;50&lt;/sub&gt; [LyeTx I mnΔK] ⋙ EC&lt;sub&gt;50&lt;/sub&gt; [LyeTx I]). In vivo data, obtained in a mouse model of septic arthritis induced by Staphylococcus aureus, showed that LyeTx I mnΔK is able to reduce infection, as demonstrated by bacterial recovery assay (∼10-fold reduction) and scintigraphic imaging (less technetium-99m labeled-Ceftizoxime uptake by infectious site). Infection reduction led to inflammatory process and pain decreases, as shown by immune cells recruitment reduction and threshold nociception increment, when compared to positive control group. Therefore, among the three shortened peptide derivatives, LyeTx I mnΔK is the best candidate as antimicrobial agent, due to its smaller amino acid sequence and toxicity, and its greater biological activity.</dcterms:abstract>
    <dc:contributor>Boff, Daiane</dc:contributor>
    <dc:contributor>de Oliveira, Patrícia Luciana</dc:contributor>
    <dc:creator>Moreira Dos Santos, Daniel</dc:creator>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Soares de Oliveira, Vívian Louise</dc:creator>
    <dc:contributor>Teixeira de Avelar Júnior, Joaquim</dc:contributor>
    <dc:contributor>Soares de Oliveira, Vívian Louise</dc:contributor>
    <dc:rights>terms-of-use</dc:rights>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <dc:contributor>Guimarães Gusmão Gomes, Karla Aparecida</dc:contributor>
    <dc:creator>de Carvalho Cruz, Rosana</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Leist, Marcel</dc:contributor>
    <dc:creator>Leist, Marcel</dc:creator>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-11-17T10:58:19Z</dcterms:available>
    <dc:creator>de Oliveira, Patrícia Luciana</dc:creator>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/51821/1/Fuscaldi_2-1me5tj5d3hi0l9.pdf"/>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/51821"/>
    <dc:creator>Boff, Daiane</dc:creator>
    <dc:creator>Guimarães Gusmão Gomes, Karla Aparecida</dc:creator>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:creator>Delp, Johannes</dc:creator>
    <dc:contributor>Fuscaldi, Leonardo Lima</dc:contributor>
    <dc:creator>Fuscaldi, Leonardo Lima</dc:creator>
  </rdf:Description>
</rdf:RDF>
kops.description.openAccessopenaccessgreen
kops.flag.etalAuthortrueeng
kops.flag.isPeerReviewedtrueeng
kops.flag.knbibliographytrue
kops.identifier.nbnurn:nbn:de:bsz:352-2-1me5tj5d3hi0l9
kops.sourcefieldExperimental Biology and Medicine. Sage Publications. 2021, <b>246</b>(4), pp. 414-425. ISSN 1535-3702. eISSN 1535-3699. Available under: doi: 10.1177/1535370220966963deu
kops.sourcefield.plainExperimental Biology and Medicine. Sage Publications. 2021, 246(4), pp. 414-425. ISSN 1535-3702. eISSN 1535-3699. Available under: doi: 10.1177/1535370220966963deu
kops.sourcefield.plainExperimental Biology and Medicine. Sage Publications. 2021, 246(4), pp. 414-425. ISSN 1535-3702. eISSN 1535-3699. Available under: doi: 10.1177/1535370220966963eng
relation.isAuthorOfPublication3bbaae39-7b18-46f6-a4f4-fb9600b5f6e5
relation.isAuthorOfPublicationd166cc79-683e-4b5f-b4a0-8ccdd3d02bbc
relation.isAuthorOfPublication.latestForDiscovery3bbaae39-7b18-46f6-a4f4-fb9600b5f6e5
source.bibliographicInfo.fromPage414
source.bibliographicInfo.issue4
source.bibliographicInfo.toPage425
source.bibliographicInfo.volume246
source.identifier.eissn1535-3699eng
source.identifier.issn1535-3702eng
source.periodicalTitleExperimental Biology and Medicineeng
source.publisherSage Publicationseng

Dateien

Originalbündel

Gerade angezeigt 1 - 1 von 1
Vorschaubild nicht verfügbar
Name:
Fuscaldi_2-1me5tj5d3hi0l9.pdf
Größe:
1.12 MB
Format:
Adobe Portable Document Format
Beschreibung:
Fuscaldi_2-1me5tj5d3hi0l9.pdf
Fuscaldi_2-1me5tj5d3hi0l9.pdfGröße: 1.12 MBDownloads: 171